⏰ Last chance! Join Premium for $20/month before it increases to $49/month.

Cartesian Therapeutics, Inc. Common Stock

$8.19
-0.02 (-0.24%)

Market Capitalization:

$247.79M

Live Price

Live Volume

Chart Volume 0
Volume 0
5 sec

Cartesian Therapeutics Market Segments

Premarket

*No Trades in Segment

Overnight

*No Trades in Segment

After Hours Yesterday

+0.00(+0.00%)
Open$8.19
Close$8.19
Low$8.19
Low Change0.00 (0.00%)
High$8.19
High Change+0.00 (+0.00%)
Range$0.00
Volume10.761K
Dollar Volume$88.13K

Regular Trading Hours Yesterday

-0.38(-4.42%)
Open$8.59
Close$8.21
Low$8.18
Low Change-0.41 (-4.77%)
High$8.88
High Change+0.29 (+3.38%)
Range$0.70
Volume72.369K
Dollar Volume$594.15K

Premarket Yesterday

+0.00(+0.00%)
Open$8.55
Close$8.55
Low$8.55
Low Change0.00 (0.00%)
High$8.55
High Change+0.00 (+0.00%)
Range$0.00
Volume701
Dollar Volume$5.99K

Cartesian Therapeutics Top Trades

We are still processing the top long and short trades for today. Please refresh the page in 10 minutes or sign up for Finsuba Premium for real time trade insights.

Cartesian Therapeutics Moving Averages

5 Day Moving Average (SMA5)$8.73
10 Day Moving Average (SMA10)$9.01
20 Day Moving Average (SMA20)$9.43
50 Day Moving Average (SMA50)$8.94
100 Day Moving Average (SMA100)$8.34
200 Day Moving Average (SMA200)$7.71

Cartesian Therapeutics Statistics

Average Volume (30 Days)118.1K
P/E Ratio (Current)-1.66
EPS (Current)-$5.09
Dividend Yield0.00%
Free Cash Flow-$78.61M
Cash Ratio7.18
Current Ratio7.48
Quick Ratio7.48
Debt to Equity-0.42
Enterprise Value$160.30M
EV to EBITDA-1.67
EV to Sales108.53
Price to Book-2.04
Price to Cash Flow
Price to Free Cash Flow
Price to Sales172.68
Return on Assets-0.48%
Return on Equity1.23%

Cartesian Therapeutics Stock Splits

There have been 2 stock splits for Cartesian Therapeutics (RNAC). The last reverse stock split occured on April 5, 2024 and reduced the outstanding shares at a ratio of 30:1.

DateTypeRatio
Apr 5, 2024Reverse30:1
Dec 1, 2023Forward1:2

Cartesian Therapeutics Dividends

There have been no dividends for Cartesian Therapeutics (RNAC).